[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eastern Cooperative Oncology Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":231},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,39,64,84,115,139,167,188,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100574232","the-ecog-acrin-support-trial-multilevel-intervention-to-improve-diverse-enrollment-in-cancer-clinical-trials-100574232",false,"NCT06756607","The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials","Inclusion Criteria:\n\nParticipant must be ≥ 18 years of age. Participant must self-identify as Black and\u002For Latino. Participant must be an oncology patient at a participating NCORP. Participant must be eligible to participate in an ECOG-ACRIN clinical trial. Participant must have the ability to understand and the willingness to sign a e-consent document.\n\nParticipant must be receiving care at a participating NCORP affiliated community oncology site.\n\nParticipant must be English or Spanish speaking to be eligible. Participant must have access to a landline, smartphone, computer, or tablet.\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":18,"type":19},500,"ESTIMATED","INTERVENTIONAL",[22],"NA","The purpose of this study is to conduct a Hybrid Type 1 cluster-randomized, roll-out effectiveness-implementation trial in NCORP community oncology practice sites (N= 500 Black and Latino cancer patients) to evaluate the effectiveness of the EA SUPPORT intervention combining CT navigators and CT research literacy tools in improving Black and Latino patient referral and accrual to NCI-supported CTs (primary outcomes) and participant and provider awareness and knowledge of CTs (secondary outcomes) while assessing implementation factors. Also, with the CUSP2CT data, Evaluation, and Coordinating Center, conduct final site evaluation and disseminate the SUPPORT intervention to NCORP community oncology sites, research bases, and affiliated trial networks.",[25],"Cancer","RECRUITING","2026-06-16",{"date":29,"type":30},"2026-06-18","ACTUAL",{"date":32,"type":30},"2025-04-25",{"date":34,"type":19},"2029-08-01",{"name":36,"class":37},"Eastern Cooperative Oncology Group","NETWORK",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100571744","phase-3-testing-whether-high-dose-chemotherapy-and-infusion-of-the-patients-own-stem-cells-improves-survival-in-patients-with-peripheral-t-cell-lymphoma-who-achieved-a-complete-response-at-the-end-of-the-initial-chemotherapy-100571744","NCT06724237","Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy","A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients With Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)","Inclusion Criteria:\n\n* Patient must be 18 to 75 years of age\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Patient must have histologically proven peripheral T-cell lymphoma (PTCL) in one of the following categories:\n\n  * Anaplastic large cell lymphoma (ALCL) ALK-negative\n  * Angioimmunoblastic T-cell lymphoma (AITL)\n  * Nodal PTCL with follicular helper T cell (TFH) phenotype\n  * Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)\n* Patient must have undergone induction treatment with an anthracycline based chemotherapy.\n\n  * NOTE: Patients who discontinued anthracycline during treatment are eligible as long as they received at least one dose and achieved complete remission\n* Patient must have achieved radiologic complete remission following induction therapy as defined by the Lugano criteria with a Deauville score between 1-3 by PET-CT\n\n  * NOTE: There is no central review required. Confirmation of complete remission status is determined by the enrolling institution's review\n  * NOTE: If a patient had a positive bone marrow biopsy at the time of initial diagnosis (pre-induction), a repeat biopsy must be completed post induction to confirm complete remission (CR)\n* Patient must be eligible for high dose chemotherapy and autologous stem cell transplant (ASCT) per the enrolling institutional guidelines at the transplant center and be ready to proceed with ASCT if randomized to the ASCT arm\n* Patient must not have active infection requiring intravenous systemic antimicrobial at time of randomization. Antibiotic prophylaxis is acceptable as long as the dose of the medication has been stable for at least 7 days prior to randomization\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse during the treatment phase of the study and thereafter according to institutional guidelines\n* Absolute neutrophil count (ANC) ≥ 1000\u002FmcL (obtained ≤ 14 days prior to protocol randomization)\n* Platelets ≥ 75,000\u002FmcL (obtained ≤ 14 days prior to protocol randomization)\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 14 days prior to protocol randomization)\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3.0 x institutional ULN (obtained ≤ 14 days prior to protocol randomization)\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load","75 Years",{"count":48,"type":19},294,[50],"PHASE3","This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. Usual treatment after a complete response may include observation or high dose chemotherapy followed by an autologous stem cell transplant, however, it is not known if a transplant if beneficial. Giving chemotherapy before a stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Stem cells removed prior to treatment are then returned to the patient to replace the blood forming cells that were destroyed by the chemotherapy. Giving high dose chemotherapy followed by an autologous stem cell transplant may be more effective compared to observation only in treating patients with peripheral T-cell lymphoma who have achieved a complete response after initial chemotherapy.",[53,54,55,56],"Anaplastic Large Cell Lymphoma, ALK-Negative","Follicular Helper T-Cell Lymphoma","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","Peripheral T-Cell Lymphoma, Not Otherwise Specified",{"date":29,"type":30},{"date":59,"type":30},"2025-01-30",{"date":61,"type":19},"2033-12-01",{"name":36,"class":37},158,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":20,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":38},"100461517","phase-2-daratumumab-for-chemotherapy-refractory-minimal-residual-disease-in-t-cell-all-100461517","NCT05289687","Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL","A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed\u002FRefractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL","Inclusion Criteria:\n\n* Patient must have documented T cell ALL and must be in first or later hematologic CR or CRi after a minimum of 2 blocks of intensive chemotherapy.\n* Patients in hematologic CR or CRi must have persistent or recurrent MRD ≥ 10-4.\n* Institution must have received central MRD status test results confirming persistent or recurrent MRD ≥ 10-4 by flow cytometry.\n* Patient may have undergone a prior allogeneic stem cell transplant, but patient may not have Grafts Versus Host Disease (GVHD) that requires ongoing immunosuppressive therapy. Patient may receive prednisone if the dose is ≤ 10 mg per day.\n* Patient must have an ECOG performance status 0-2.\n* All patients of childbearing potential must have a blood test or urine study within 14 days prior to Step 1 registration to rule out pregnancy.\n* Patients must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and continue to 3 months after the last dose of protocol treatment. Patients must also agree to abstain from donating sperm, even if they have had a successful vasectomy, or donating eggs while on study treatment and for 3 months after the last dose of protocol treatment.\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible.\n* Patient must have adequate organ and marrow function as defined below (these labs must be obtained ≤ 7 days prior to Step 1 registration).\n* Absolute neutrophil count (ANC) ≥ 750\u002FμL\n* Platelets ≥ 75,000\u002FμL\n* Total or Direct bilirubin ≤ 2 mg\u002FdL\n* AST(SGOT)\u002FALT(SGPT) ≤ 3.0 × institutional ULN\n* Creatinine ≤ 1.5 x institutional ULN or Creatinine Clearance \\> 30 ml\u002Fmin\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with prior CNS involvement are eligible as long as they do not have active CNS involvement at time of Step 1 registration.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n\nExclusion Criteria:\n\n-Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used",{"count":72,"type":19},20,[74],"PHASE2","In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.",[77],"T-cell Acute Lymphoblastic Leukemia",{"date":29,"type":30},{"date":80,"type":30},"2023-05-25",{"date":82,"type":19},"2027-06-30",{"name":36,"class":37},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":20,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},"100447581","improving-adolescent-and-young-adult-self-reported-data-in-ecog-acrin-trials-100447581","NCT05108298","Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials","Inclusion Criteria:\n\nPatient must be ≥ 18 years and ≤ 39 years of age at registration. Patient must have a histologically confirmed diagnosis of primary cancer of any stage within 12 weeks (84 days) at registration.\n\nPatient must have received, be currently receiving or planning to receive treatment for cancer, including surgery and\u002For chemotherapy and\u002For radiation therapy.\n\nPatient must have an ECOG performance status 0-3. Patient must have a life expectancy \\>24 months. Patient must be able to complete questionnaires in English. Patient must have internet access through computer, tablet, or smartphone. Patient must have an email address. Patient must have a mobile phone able with text messaging capabilities. Patient must be able to accurately provide self-report data (e.g. per clinical judgment, cognitive function is intact).\n\nPatient must be able to provide informed consent.\n\nExclusion Criteria:\n\nPatient must not have a recurrence or second primary cancer. Patients must not have basal cell skin carcinoma.","39 Years",{"count":92,"type":19},400,[22],"The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.",[96,97,98,99,100,101,102,103,104,105,106,107],"Breast Cancer, NOS","CNS Primary Tumor, NOS","Cervical Cancer, NOS","Colorectal Cancer, NOS","Leukemia, NOS","Lymphoma, NOS","Miscellaneous Neoplasm, NOS","Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS","Testicular Nonseminomatous Germ Cell Tumor, NOS","Thyroid Cancer, NOS","Melanoma","Bone Cancer, NOS",{"date":29,"type":30},{"date":110,"type":30},"2021-11-10",{"date":112,"type":19},"2027-05-01",{"name":36,"class":37},347,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":20,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":38},"100598175","phase-3-a-randomized-phase-iii-study-of-management-of-treatment-naive-primary-melanoma-in-elderly-patients-100598175","NCT07068074","A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients","Inclusion Criteria:\n\n* Patient must be ≥ 75 years of age.\n* Patient must have ECOG Performance Status of 0-2.\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible.\n* Patient must have newly diagnosed primary cutaneous melanoma with wide local excision (WLE) and sentinel lymph node (SLN) biopsy indicated per the treating physician, pending definitive surgical management.\n* Patient must be eligible for WLE and SLN biopsy. Patients for whom SLN biopsy would be contraindicated, difficult to perform (i.e., after prior surgery in the draining basin) or impossible (i.e., after prior lymphadenectomy for another cause) are not eligible.\n* Patient must be eligible for surgery and not have uncontrolled medical condition that in the opinion of the medical or surgical oncologist precludes surgical management.\n* Patient must be English or Spanish speaking to be eligible for this study in order to complete the patient-reported outcomes (PROs). Patients who speak only French can be enrolled in Canada and appropriate documents will be made available by the study team.\n\nExclusion Criteria:\n\n* Patient must not have an active infection that precludes enrollment to this study in opinion of treating investigator.\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.",{"count":122,"type":19},428,[50],"Can we treat your melanoma just as effectively without doing a sentinel lymph node (SLN) biopsy in addition to your wide local excision (WLE) procedure? A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue. This is sometimes followed by a sentinel lymph node (SLN) biopsy, in which lymph nodes that cancer cells could spread to are removed as well.\n\nWe are doing this study because we want to find out if performing the WLE alone is just as effective as the usual approach for your melanoma, and if it leads to improvements in patients' overall well-being. The usual approach is defined as care most people get for the early stage of melanoma that you currently have.",[126],"Cutaneous Melanoma",[119,128,129],"cutaneous melanoma","Naive Primary Melanoma in Elderly Patients","NOT_YET_RECRUITING","2025-11-11",{"date":133,"type":30},"2025-11-13",{"date":135,"type":19},"2025-12-12",{"date":137,"type":19},"2031-01-01",{"name":36,"class":37},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":148,"minAge":16,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":20,"phases":151,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":38},"100602360","a-targeted-electronic-health-approach-to-reduce-fear-of-recurrence-in-breast-cancer-survivors-fortitude-100602360","NCT07122492","A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)","Randomized Controlled Trial of FoRtitude: Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors in Community Oncology Settings","FoRtitude","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age.\n* Participant must have had histologically confirmed Stage 0-III breast cancer at time of diagnosis.\n* Participant must have completed primary treatment 1-10 years prior to Step 0 registration.\n\nNOTE: Current hormonal therapy is allowed. NOTE: Primary treatment can include chemotherapy and\u002For surgery and\u002For radiation therapy.\n\n\\- Participant must be receiving their care (cancer treatment or survivorship care) from an oncology provider affiliated with the NCORP site and are expected to continue care at the site for the next 18 months.\n\nNOTE: This eligibility criteria is intended to ensure access to healthcare utilization data. Oncology provider can include an Advance Practice Provider, Advance Nurse Practitioner, oncologist, primary care provider, or nurse or physician responsible for survivorship care.\n\n* Participant must have no evidence of active cancer of any type at the time of Step 0 registration (per the assessment of the physician), excluding local basal cell or squamous cell carcinoma.\n* Participant must be fluent in written and spoken English.\n* Participant must have an ECOG Performance Status of 0-2.\n* Participant must have the ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) are not eligible.\n* Participant must complete the FCRI 9-item severity scale and report a score of 13 or higher.\n* Participant must have access to the internet (via smartphone, tablet, or computer).\n\nNOTE: The restriction to those with internet access is based on the primary intention of the study which involves internet-based delivery intervention content delivered via the internet.\n\n* Participant must have completed the Baseline Assessment within 60 days of Step 0 registration.\n* Randomization to Step 1 must occur within 60 days of Step 0 registration.\n\nExclusion Criteria:\n\n* Participant must not have any psychiatric or cognitive conditions that may affect the participant's ability to accurately provide self-report data, per clinical discretion.",true,"FEMALE",{"count":150,"type":19},800,[22],"The goal of this study is to determine if the intervention or if general information about being a breast cancer survivor can help Breast Cancer Survivors reduce their fear of recurrence. The main question it aims to answer are:\n\nCan the FoRtitude intervention lower the fear of recurrence for Breast Cancer Survivors?\n\nParticipants will:\n\nAnswer questions about their fear of recurrence. Be randomized to 1 of the 3 following options: (1) a weblink to access an eHealth intervention which includes a website and an optional interactive text-messaging feature, (2) a weblink to a non-interactive website that will include links to external websites with general information that may be helpful for Breast Cancer Survivors, or (3) you will need to talk with your oncology team about your concerns about recurrence or seek psychosocial care in the community.\n\nBe asked to fill out questionnaires 5 times for up to 18 months.",[154,155],"Breast Cancer Survivor","Fear of Cancer Recurrence",[157,158],"Breast cancer survivor","Fear of recurrence","2025-08-07",{"date":161,"type":30},"2025-08-14",{"date":163,"type":19},"2025-09-01",{"date":165,"type":19},"2029-09-01",{"name":36,"class":37},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":20,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":187,"locationsCount":38},"100596040","phase-2-testing-the-effect-of-sulforaphane-a-compound-naturally-found-in-cruciferous-vegetables-on-preventing-melanoma-in-patients-with-a-prior-history-of-melanoma-100596040","NCT07040280","Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma","A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma","Inclusion Criteria:\n\n* Patient must have ≥ 3 clinically atypical nevi, assessed within 30 days prior to randomization, that are consistent with the International Agency for Research on Cancer (IARC) definition as follows.27\n* Must have a diameter of ≥ 5mm in one dimension\n* Must include a macular component in at least one area\n* Must have at least two of the following features: ill-defined borders, color variegation, uneven contour, and erythema\n* Patient must have a prior diagnosis of early-stage melanoma, defined as either melanoma in situ, localized resected stage I-II node negative melanoma, or resected node positive stage III melanoma who in the assessment of their physician have a low risk of relapse of their prior melanoma within one year of randomization.\n* Patient must not be currently on targeted or checkpoint immunotherapy or treated within 365 days prior to randomization.\n* Patient must be ≥ 18 years of age.\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible.\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with a prior or concurrent malignancy (other than the melanoma for which they are on this study), whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen, are eligible for this trial.\n\nExclusion Criteria:\n\n* Patient must not be pregnant.\n* Patient must not have a known allergy to cruciferous vegetables.\n* Patients must not use any other sulforaphane-containing dietary supplement during the study period.\n* Patient must not be on any current systemic treatment for melanoma.",{"count":175,"type":19},120,[74],"The goal of this clinical trial is to compare the safety and effects of sulforaphane with the safety and effects of placebo on people's risk of developing melanoma. The main question it aims to answer is:\n\nWill giving sulforaphane (a broccoli sprout extract) have a meaningful effect on how your atypical moles change over time? If there is an effect, will this lower your risk of developing melanoma?\n\nParticipants will:\n\nTake sulforaphane or a placebo for 12 months Visit the clinic once every 3 months for checkups and tests You will keep a calendar which will help you keep track of when you take your tablets",[106],[106,180],"Skin Neoplasm","2025-06-24",{"date":183,"type":30},"2025-06-27",{"date":185,"type":19},"2025-10-31",{"date":34,"type":19},{"name":36,"class":37},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":148,"minAge":16,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100576537","extended-clinical-follow-up-and-biospecimen-collection-for-patients-enrolled-in-tailorx-and-rxponder-a-companion-protocol-100576537","NCT06786585","Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol","Inclusion Criteria:\n\n* Patient must have met the criteria for 1 of the 3 possible cohorts described below:\n\n  1. Cohort 1: Previously enrolled on TAILORx (PACCT-1) with recurrence score (RS) 0-100 AND had a biopsy-confirmed locoregional, distant, or both locoregional and distant recurrence prior to registration on this protocol.\n  2. Cohort 2: Previously enrolled on Step 2 of RxPONDER (S1007) with a recurrence score (RS) of 0-25 AND had a biopsy-confirmed locoregional, distant, or both locoregional and distant recurrence prior to registration on this protocol.\n  3. Cohort 3: Previously enrolled on Step 1 of RxPONDER and found to have a high Oncotype DX RS 26-100.\n* Patient must have been a TAILORx (RS 0-100) or RxPONDER (RS 0-100) study participant who has the ability to understand and the willingness to sign a written informed consent document for participation in this non-intervention study (cohorts 1, 2, or 3). Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible.\n* Patient must have tumor tissue available from each cohort as outlined below:\n* Patients from Cohorts 1 and 2 must have relapse tumor tissue specimen available at the time of registration for submission to ECOG-ACRIN Central Biorepository and Pathology Facility within 30 days of registration.\n* Patients from Cohort 3 must have primary tumor tissue specimen available at time of EA1241 registration for submission to ECOG-ACRIN Central Biorepository and Pathology Facility within 30 days of registration\n\nExclusion Criteria:",{"count":195,"type":19},600,"OBSERVATIONAL","The purpose of this study is to retrieve tissue samples from individuals with breast cancer who previously enrolled on the PACCT-1 (TAILORx) or S1007 (RxPONDER) trials and experiences a recurrence of their cancer (Cohort 1, 2, and 3), and\u002For the tumor initially removed at surgery in patients previously enrolled in step 1 of S1007 (RxPONDER) and found to have a high Recurrence Score of 26-100 (Cohort 3) but not followed on the study after that point. The tissue will be used for future research designed to understand why breast cancer recurs despite hormonal therapy or chemotherapy plus hormonal therapy.",[199],"Breast Cancer","2025-05-28",{"date":202,"type":30},"2025-05-30",{"date":204,"type":19},"2025-06",{"date":206,"type":19},"2028-04",{"name":36,"class":37},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":20,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100487556","phase-2-testing-the-use-of-combination-therapy-in-patients-with-persistent-low-level-acute-myeloid-leukemia-aml-following-initial-treatment-100487556","NCT05628623","Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment","Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial","ERASE","Inclusion Criteria:\n\n* Patient must be ≥ 18 and ≤ 59 years of age.\n* Patient must have ECOG performance status 0-2\n* Patient must have morphologically documented AML or secondary AML \\[from prior conditions such as myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN)\\] or therapy related AML (t-AML), as defined by World Health Organization (WHO) criteria\n* Patient must have completed induction chemotherapy in a myeloMATCH Young Adult Tier-1 protocol. Patient may have received prior hypomethylating agents (HMAs). Patient may have received prior azacitidine + venetoclax.\n* Patient must have been assigned to this protocol by myeloMATCH MSRP\u002FMATCHBOX\u002F. Patients thereby assigned will have attained complete remission (CR) or CR with partial hematologic recovery (CRh) (defined as CR with (ANC) ≥ 500\u002FmcL and\u002For platelets \\> 50\u002FmcL) with detectable MRD at time of assignment. MRD is defined as \\>0.1% flow cytometry on bone marrow (BM) biopsy as assessed by MDNet. The definition of CR or CRh may be made ± 2 weeks from BM biopsy\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible.\n* Patient must have recovered (i.e.: resolved to \\\u003C grade 2) from adverse events related to prior anti-cancer therapy at the time of randomization with the exception of alopecia\n* Patient must have adequate organ and marrow function as defined below (these labs must be obtained ≤ 7 days prior to protocol randomization):\n\nAbsolute neutrophil count (ANC) ≥ 500\u002FmcL ANC:\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ Date of Test:\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ Platelets ≥ 50,000\u002FmcL Platelets:\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ Date of Test:\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ Total bilirubin ≤ 2 x institutional upper limit of normal (ULN) Total Bilirubin:\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ Institutional ULN:\\_\\_\\_\\_\\_\\_\\_\\_\\_ Date of Test:\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ AST(SGOT)\u002FALT(SGPT) ≤ 3.0 × institutional ULN AST:\\_\\_\\_\\_\\_\\_\\_ Institutional ULN:\\_\\_\\_\\_\\_\\_\\_\\_\\_ Date of Test:\\_\\_\\_\\_\\_\\_\\_ ALT: \\_\\_\\_\\_\\_\\_\\_Institutional ULN:\\_\\_\\_\\_\\_\\_\\_\\_\\_ Creatinine ≤ 1.5 x institutional ULN Creatinine \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_Date of Test:\\_\\_\\_\\_\\_\\_\\_\\_ OR\n\n≥ 50 mL\u002Fmin\u002F1.73 m2\n\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients must be able to swallow oral tablets and be free of GI absorption issues.\n\nExclusion Criteria:\n\n* Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.\n\nAll patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.\n\nA patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).\n\nPatient of child bearing potential? \\_\\_\\_\\_\\_\\_ (Yes or No) Date of blood test or urine study: \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n* Patients of childbearing potential and\u002For sexually active patients must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and continue for 6 months after the last dose of daunorubicin + cytrarabine liposome, 6 months after the last dose of azacitidine for patients of childbearing potential, 3 months after the last dose of azacitidine for male patients, and for 30 days after the last dose of venetoclax. Patient must also abstain from nursing an infant for 2 weeks after the last dose of daunorubicin + cytrarabine liposome and for 1 week after the last dose of azacitidine.\n* Patients must not have FLT3 TKD or ITD mutation. Patients with this mutation, will be excluded from this study because myeloMATCH plans separate studies in tier-2 for those patients\n* Patient must not be receiving any other investigational agents at the time of randomization.\n* Patient must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to cytarabine, azacitidine, venetoclax or Daunorubicin and Cytarabine liposome\n* Patients must not have uncontrolled intercurrent illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or serious chronic gastrointestinal conditions associated with diarrhea","59 Years",{"count":218,"type":19},184,[74],"ERASE is part of the MyeloMATCH initiative, Young Adult Basket and is a Tier 2 study. The study is comparing the use of Cytarabine to Cytarabine and Venetoclax, Daunorubicin\u002FCytarabine Liposome and Venetoclax, and Azacitidine and Venetoclax.",[222],"Leukemia, Myeloid, Acute","2024-06-29",{"date":225,"type":30},"2024-07-03",{"date":227,"type":19},"2024-10-23",{"date":229,"type":19},"2027-02",{"name":36,"class":37},""]